Cohance Lifesciences Ltd approves Q2/H1 FY27 results, with Q2 revenue of ₹476.65 crore and profit attributable to shareholders of ₹15.22 crore.
- Q2 revenue rose 12.9% sequentially but fell 14.2% year on year; adjusted EBITDA margin was 10%, versus 2.2% in Q1.
- Appointed Dr. Kuber Jagdale Chief Technical Officer and Executive Director for five years from 7 November 2026.
- Approved a proposed 26% investment in a solar-power SPV for captive consumption.
- Telangana Pollution Control Board issued a closure order for the Suryapet facility following a fatal industrial accident; limited-review conclusions were unmodified.
